Featured News
Advancing CAR-T Therapy with PDX Models
PDX Models Drive Safer, Faster Pathways for Personalized Cancer Care
Charles River has joined the EU backed EASYGEN Consortium to transform CAR-T therapy delivery. Currently, manufacturing CAR-T treatments can take weeks in centralized facilities, delaying care and limiting access. EASYGEN aims to change that by developing an automated, hospital-based platform capable of producing CAR-T therapies within 24 hours.
Julia Schueler discusses insights on how in silico, in vitro, and in vivo, PDX tools can optimize your preclinical phase, thanks to translationally relevant tumor biology models.
Watch the Webinar
For clients, this collaboration means earlier insights and streamlined workflows for advanced therapies. Charles River will contribute its expertise through a 3D ex vivo screening platform, leveraging its patient-derived xenograft (PDX models) biobank and advanced imaging to ensure each therapy is safe and effective before reaching patients. These PDX models provide predictive data that help clients optimize CAR-T candidates quickly and confidently.
In the treatment of complex cancers, time is critical. The current manufacturing process for CAR-T therapies is time intensive and severely limits their clinical application. By collaborating across industry and academia, I am hopeful we can design a streamlined workflow that will increase access to these therapies for patients who need them.”
Julia Schueler, DVM, PhD, Oncology Therapeutic Area Lead at Charles River
Supported by Horizon Europe’s Innovative Health Initiative, EASYGEN unites 18 partners across eight countries with a single mission: to make personalized cell therapies faster, safer, and more accessible because every moment matters.